Relay Therapeutics, Inc.
RLAYNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $3.69B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $5.95$21.27
- Volume (live)
- -
- Avg. volume (3M)
- 2.96M
Relay Therapeutics (RLAY) Stock Price & Financial Analysis
Relay Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $17.68 - $18.27 |
|---|---|
| 52-Week High | $21.27 |
| 52-Week Low | $5.95 |
| Open | $18.03 |
| Volume (last close) | 1.90M |
| Average Volume (3M) | 2.96M |
| Revenue (TTM) | 10.35M |
|---|---|
| Net Income (TTM) | -286.04M |
| Free Cash Flow (TTM) | -212.21M |
| EPS (TTM) | −$1.57 |
| Profit Margin | -2763.64% |
| Operating Margin | -2999.37% |
| Return on Equity (ROE) | -32.14% |
| Debt to Equity | 0.03 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 3.69B |
|---|---|
| Shares Outstanding | 202.85M |
| Price to Sales (P/S) | 356.31 |
| Price to Book (P/B) | 4.14 |
| EV/EBITDA | -12.29 |
| 50-Day MA | $18.76 |
|---|---|
| 200-Day MA | $14.57 |
| 1-Year Change | +171.30% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Relay Therapeutics at a Glance
As of the Oct 23, 2026 close, Relay Therapeutics (RLAY) has a market capitalization of $3.69B. The stock trades at 356.3× sales. Over the trailing twelve months it lost $286.04M on revenue of $10.35M and burned $212.21M of free cash flow. Revenue grew 23.9% year over year.
As of its latest reported balance sheet, it holds $121.19M in cash and securities against $30.66M of debt, a net cash position of $90.53M.
Relay Therapeutics does not currently pay a dividend.
The share price is up 171.3% over the past year. At $18.18 (the Oct 23, 2026 close) it sits within its 52-week range of $5.95 to $21.27, above its 200-day moving average of $14.57.
Based on 10 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $27.14, 49.3% above the Oct 23, 2026 close.
Frequently Asked Questions About Relay Therapeutics
What is the current stock price for RLAY?
As of the Oct 23, 2026 close, RLAY stock trades at $18.18. The 52-week range is $5.95–$21.27, with a day range of $17.68–$18.27.
What is the P/E ratio for RLAY?
The P/E ratio (Price-to-Earnings) for RLAY is shown in the Key Statistics section. This valuation metric helps compare Relay Therapeutics, Inc. to industry peers.
Does RLAY pay dividends?
Relay Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for RLAY?
Based on ratings from 10 professional analysts over the last 90 days, the consensus for RLAY is Buy. The average 12-month price target is $27.14, a 49.3% upside from the Oct 23, 2026 close of $18.18.
What is the market cap of RLAY?
As of the Oct 23, 2026 close, Relay Therapeutics's market capitalization is $3.69B, classifying it as a mid-cap company. Relay Therapeutics operates in the Healthcare sector within the Biotechnology industry.